1186TiP EPONA, efficacy of osimertinib with platinum and pemetrexed in EGFR mutant non-small cell lung cancer patients bearing CNS metastasis, and have systemic progression but stable intracranial disease on OsimertiNib resistAnce (TORG 1938)

Abstract

Central nervous system (CNS) protection is a crucial strategy for the long-term survival of patients (pts) with cancer. Currently, pts with epidermal growth factor receptor (EGFR)-mutant (mt) non-small cell lung cancer (NSCLC) have expected longer survival after treatment with EGFR-TKIs. Osimertinib is a current standard of care (SOC) for EGFR-mt NSCLC and has been clinically shown to control the CNS progression. The current SOC involves switching to platinum doublet chemotherapy and discontinuing osimertinib if the CNS is under control after progression at other sites.